More recently, Zhang et al. (2025) employed PD-1-targeted nanocarriers to enhance the delivery of curcumol in prostate cancer models, underscoring the importance of PDCD1 not only in immune modulation but also in targeted therapeutic strategies [35]. Here, PDCD1 is linked to prostate carcinoma.